User profiles for Robert S. Wallis
Robert S. Wallis, MD, FIDSACSO, Aurum Institute; Prof Medicine, CWRU & Vanderbilt Verified email at po.cwru.edu Cited by 15849 |
Biomarkers and diagnostics for tuberculosis: progress, needs, and translation into practice
Human infection with Mycobacterium tuberculosis can progress to active disease, be
contained as latent infection, or be eradicated by the host response. Tuberculosis diagnostics …
contained as latent infection, or be eradicated by the host response. Tuberculosis diagnostics …
The risk of tuberculosis related to tumour necrosis factor antagonist therapies: a TBNET consensus statement
…, B Hellmich, R Groves, S Schreiber, RS Wallis… - 2010 - Eur Respiratory Soc
Anti-tumour necrosis factor (TNF) monoclonal antibodies or soluble TNF receptors have
become an invaluable treatment against chronic inflammatory diseases, such as rheumatoid …
become an invaluable treatment against chronic inflammatory diseases, such as rheumatoid …
[HTML][HTML] High-dose rifampicin, moxifloxacin, and SQ109 for treating tuberculosis: a multi-arm, multi-stage randomised controlled trial
Background Tuberculosis is the world's leading infectious disease killer. We aimed to
identify shorter, safer drug regimens for the treatment of tuberculosis. Methods We did a …
identify shorter, safer drug regimens for the treatment of tuberculosis. Methods We did a …
[HTML][HTML] Host-directed immunotherapy of viral and bacterial infections: past, present and future
The advent of COVID-19 and the persistent threat of infectious diseases such as tuberculosis,
malaria, influenza and HIV/AIDS remind us of the marked impact that infections continue to …
malaria, influenza and HIV/AIDS remind us of the marked impact that infections continue to …
Depressed T-cell interferon-γ responses in pulmonary tuberculosis: analysis of underlying mechanisms and modulation with therapy
…, SK Schwander, S Robertson, RS Wallis… - Journal of Infectious …, 1999 - academic.oup.com
Immunological and clinical profiles were evaluated in 2 groups: human immunodeficiency
virus (HIV)—uninfected and HIV-infected patients, with newly diagnosed pulmonary …
virus (HIV)—uninfected and HIV-infected patients, with newly diagnosed pulmonary …
Advancing host-directed therapy for tuberculosis
RS Wallis, R Hafner - Nature Reviews Immunology, 2015 - nature.com
Improved treatments are needed for nearly all forms of Mycobacterium tuberculosis infection.
Adjunctive host-directed therapies have the potential to shorten tuberculosis treatment …
Adjunctive host-directed therapies have the potential to shorten tuberculosis treatment …
Tuberculosis—advances in development of new drugs, treatment regimens, host-directed therapies, and biomarkers
Tuberculosis is the leading infectious cause of death worldwide, with 9·6 million cases and 1·5
million deaths reported in 2014. WHO estimates 480 000 cases of these were multidrug …
million deaths reported in 2014. WHO estimates 480 000 cases of these were multidrug …
Tumour necrosis factor antagonists: structure, function, and tuberculosis risks
RS Wallis - The Lancet infectious diseases, 2008 - thelancet.com
Our understanding of the infection risks presented by tumour necrosis factor (TNF) antagonists
has continued to evolve in the 10 years since these drugs were first introduced. Several …
has continued to evolve in the 10 years since these drugs were first introduced. Several …
[HTML][HTML] Host-directed therapies for infectious diseases: current status, recent progress, and future prospects
Despite extensive global efforts in the fight against killer infectious diseases, they still cause
one in four deaths worldwide and are important causes of long-term functional disability …
one in four deaths worldwide and are important causes of long-term functional disability …
Tuberculosis biomarkers discovery: developments, needs, and challenges
Biomarkers are indispensable to the development of new tuberculosis therapeutics and
vaccines. The most robust biomarkers measure factors that are essential to the underlying …
vaccines. The most robust biomarkers measure factors that are essential to the underlying …